The Latest Cardiac and Vascular News
MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDyne Inc. (“VDyne”), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of Mike Buck as Chairman and Chief Executive Officer. Mr. Buck brings more than 30 years of leadership experience in cardiovascular medical […]
HAMBURG, Germany & MUNICH–(BUSINESS WIRE)–GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated […]
Collaboration focuses on advancing responsible and evidence-based digital innovation in preventive heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the leading digital heart health platform, today announced a strategic collaboration with the American College of Cardiology (ACC), a global organization dedicated to transforming cardiovascular care and improving heart health for all. As part […]
LAUSANNE, Switzerland & PALO ALTO, Calif.–(BUSINESS WIRE)–Polares Medical SA (“Polares”), a clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement (PLR) system for mitral regurgitation (MR), today announced the closing of a $50 million Series C financing. The oversubscribed financing was achieved with strong participations from DC Global Ventures, Lumination Partners, existing investors, and a new strategic investor. Polares is focused on the large and grow
Trusted leader in clinical guidance releases new updates for cardiovascular surgery, gene therapy, and orthopedic procedures SEATTLE, March 3, 2026 /PRNewswire/ — MCG Health, part of the Hearst Health network, today announced the release of its updated decision support solutions and the…
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional.
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
ANN ARBOR, Mich. & HENDERSON, Nev.–(BUSINESS WIRE)– #CHF–Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia
WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase 240,000 additional shares, at a price to the public of $125.00 per share. The aggregate gross proceeds to Palvella from this offering, before deducting underwriting discounts and commissions and offering expenses, were $230.0 million.
Spinoff from Novartis AG’s acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively SAN DIEGO, Feb. 27,…
